scholarly journals Loss of skeletal muscle mass after curative gastrectomy is a poor prognostic factor

Author(s):  
Naruji Kugimiya ◽  
Eijiro Harada ◽  
Kazuhito Oka ◽  
Daichi Kawamura ◽  
Yuki Suehiro ◽  
...  
2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Song Ee Park ◽  
Jin Hwa Choi ◽  
Jae Yong Park ◽  
Beom Jin Kim ◽  
Jae Gyu Kim ◽  
...  

Abstract Cancer causes muscle mass loss, which is associated with a poor prognosis. Chemotherapy may also reduce muscle mass. We investigated skeletal muscle mass change during palliative chemotherapy for advanced gastric cancer (AGC) and its association with treatment outcomes. We retrospectively reviewed 111 consecutive AGC patients who underwent first-line palliative chemotherapy. Skeletal muscle area was measured before and after chemotherapy at the third lumbar vertebra level using computed tomography scans. We compared skeletal muscle index (SMI), body mass index (BMI), and body weight changes to chemotherapy response and survival. The 80 male and 31 female patients’ median age was 65 (range 31–87) years, and 46.8% had sarcopenia at baseline. Median pre-chemotherapy to post-chemotherapy SMI, BMI, and body weight decreases were − 4.5 cm2/m2 (− 11.3%) (P < 0.001); − 0.7 kg/m2 (− 3.2%) (P < 0.001); and − 2.0 kg (− 3.5%) (P < 0.001), respectively. Median SMI decreases for patients with objective response, stable disease, and disease progression were − 4.0 cm2/m2 (range − 20.1 ~ 9.5); − 4.5 cm2/m2 (range − 19.8 ~ 0.8); and − 3.8 cm2/m2 (range: − 17.6 ~ 0.1), respectively. Response to chemotherapy was not associated with SMI decrease (P = 0.463). In multivariable analysis, sarcopenia at baseline (HR 1.681; 95% CI 1.083–2.609, P = 0.021), decreased SMI (HR 1.620; 95% CI 1.041–2.520; P = 0.032) were significant poor prognostic factors for survival. Skeletal muscle mass decreased significantly during chemotherapy in AGC patients, but was not associated with chemotherapy response. Decreased SMI was a poor prognostic factor in AGC patients during first-line palliative chemotherapy.


Digestion ◽  
2018 ◽  
Vol 99 (1) ◽  
pp. 79-85 ◽  
Author(s):  
Yuji Miyamoto ◽  
Yukiharu Hiyoshi ◽  
Takahiko Akiyama ◽  
Yuki Kiyozumi ◽  
Kojiro Eto ◽  
...  

2017 ◽  
Vol 28 ◽  
pp. vi49
Author(s):  
D. Basile ◽  
A. Parnofiello ◽  
M.G. Vitale ◽  
F. Cortiula ◽  
S.K. Garattini ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
R. Mallet ◽  
P. Decazes ◽  
R. Modzelewski ◽  
J. Lequesne ◽  
P. Vera ◽  
...  

AbstractLow skeletal muscle mass is a well-known prognostic factor for patients treated for a non-small-cell lung cancer by surgery or chemotherapy. However, its impact in patients treated by exclusive radiochemotherapy has never been explored. Our study tries to evaluate the prognostic value of low skeletal muscle mass and other antropometric parameters on this population. Clinical, nutritional and anthropometric date were collected for 93 patients treated by radiochemotherapy for a NSCLC. Anthropometric parameters were measured on the PET/CT by two methods. The first method was a manual segmentation at level L3, used to define Muscle Body Area (MBAL3), Visceral Fat Area (VFAL3) and Subcutaneous Fat Area (SCFAL3). The second method was an software (Anthropometer3D), allowing an automatic multislice measurement of Lean Body Mass (LBMAnthro3D), Fat Body Mass (FBMAnthro3D), Muscle Body Mass (MBMAnthro3D), Visceral Fat Mass (VFMAnthro3D), and Sub-Cutaneous Fat Mass (SCFMAnthro3D) on the PET/CT. All anthropometrics parameters were normalised by the patient's height. The primary end point was overall survival time. Univariate and then stepwise multivariate cox analysis were performed for significant parameters. Finally, Spearman's correlation between MBAL3 and MBMAnthro3D was assessed. Forty-one (44%) patients had low skeletal muscle mass. The median overall survival was 18 months for low skeletal muscle mass patients versus 36 months for non-low skeletal muscle mass patients (p = 0.019). Low skeletal muscle mass (HR = 1.806, IC95% [1.09–2.98]), serums albumin level < 35 g/l (HR = 2.203 [1.19–4.09]), Buzby Index < 97.5 (HR = 2.31 [1.23–4.33]), WHO score = 0 (HR = 0.59 [0.31–0.86] and MBMAnthro3D < 8.56 kg/m2 (HR = 2.36 [1.41–3.90]) were the only significant features in univariates analysis. In the stepwise multivariate Cox analysis, only MBMAnthro3D < 8.56 kg/m2 (HR = 2.16, p = 0.003) and WHO score = 0 (HR = 0.59, p = 0.04) were significant. Finally, muscle quantified by MBAL3 and MBMAnthro3D were found to be highly correlated (Spearman = 0.9). Low skeletal muscle mass, assessed on the pre-treatment PET/CT is a powerful prognostic factor in patient treated by radiochemotherapy for a NSCLC. The automatic software Anthropometer3D can easily identify patients a risk that could benefit an adapted therapy.


2018 ◽  
Vol 31 (Supplement_1) ◽  
pp. 172-172
Author(s):  
Daisuke Soma ◽  
Kazuhiko Yamada ◽  
Kyoko Nohara ◽  
Satoshi Yamashita ◽  
Hitomi Wake ◽  
...  

Abstract Background An inflammation-based prognostic score, the modified Glasgow Prognostic Score (mGPS), has been established as a useful tool for predicting postoperative outcome in patients with cancer. Recently, depletion of skeletal muscle mass (sarcopenia) has been linked to poor outcome in several types of cancers. In this study investigated the relationship between these factors in patients with operable esopahgeal cancer. Methods Skeletal muscle mass was assessed in 87 patients who underwent esophagectomy from Jan. 2014 to Dec. 2016. The skeletal muscle tissue areas were measured by the ZioStation. The evaluated samples were slices of the third lumbar vertebrae (L3) in the inferior direction. The muscle area normalized by the square of the height (m2) is called the skeletal muscle index (SMI) (cm2/m2). The modified Glasgow prognostic score (mGPS) was measured using C-reactive protein (CRP) and albumin levels (mGPS 2: CRP > 1.0 mg/dL and albumin < 3.5 g/dL; mGPS 1: CRP > 1.0 mg/dL; mGPS 0: CRP ≤ 1.0 mg/dL). Patients were given mGPS- L group(mGPS0)or mGPS- H(mGPS1,2). Results The decrease of the skeletal muscle was higher in the mGPS2 than in the mGPS0. The rate of respiratory complications significantly higher in the sarcopenia group than in the non-sarcopenia group (P = 0.01). For other complications the differences were not significant. Kaplan-Meier analysis and log-rank test revealed that Sarcopenia and mGPS-H predicted a higher risk of mortality (P = 0.0034 and 0.0001). Univariate analyses revealed that the mGPS, Stage and Sarcopenia were associated with mortality. Multivariate analyses using these 3 factors revealed that only mGPS (HR: 3.18; 95% CI: 1.70–8.70; P = 0.02) and Sarcopenia (HR: 3.39; 95% CI: 1.27–10.6; P = 0.01) were an independent risk factor of mortality. Conclusion The mGPS was closely related on the progression of sarcopenia, and both the mGPS-H and Sarcopenia were poor prognostic factor respectively. Disclosure All authors have declared no conflicts of interest.


Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 3322-3322
Author(s):  
Yasuhiko Shibasaki ◽  
Kenta Kobayashi ◽  
Tatsuya Suwabe ◽  
Kyoko Fuse ◽  
Miwako Narita ◽  
...  

Introduction Depletion of skeletal muscle is a poor prognostic factor for patients with various malignancies; however its significance for allogeneic hematopoietic cell transplantation (allo-HCT) in patients with hematological disease is unclear. Generally, muscle mass is measured by the methods established by the European Working Group on Sarcopenia in Older People, which require the use of dual energy X-ray absorptiometry or bioimpedance analysis, methods that are not performed in routine practice. Therefore, cross-sectional imaging using computed tomography (CT) has been suggested as an alternative method for analyzing muscle mass in clinical practice. Especially, lumbar total muscle cross-sectional area using CT, normalized for body height, which was named lumbar skeletal muscle mass index (SMI), is reported as an indicator of nutritional status, sarcopenia and cancer cachexia in patients with solid organ malignancy. Aims To clarify the usefulness of a pre-transplant lumber SMI as a prognostic indicator for allo-HCT patients. Methods Among 208 patients with hematological disease who underwent allo-HCT between 2006 and 2017 at our facility, 191 patients (95 males and 96 females) underwent CT scans for routine pre-transplant status assessment. Ninety patients had acute myeloid leukemia, 38 patients had acute lymphoblastic leukemia, 24 patients had myelodysplastic syndrome, 20 patients had malignant lymphoma, and 19 patients had other diseases. The median age of the patients was 42 years old (range: 16-66 years). Seventy-eight patients received myeloablative conditioning and the others received reduced intensity conditioning regimens. The number of patients in each HCT-comorbidity index (HCT-CI) risk group was as follows: low: 72, intermediate: 54 and high: 65. Axial images at the iliac crest were selected for analysis of lumber total muscle cross-sectional area (cm2). The rectus abdominus, psoas and paraspinal muscles were identified and quantified. Lumbar total muscle cross-sectional area was normalized for body height in meters squared (m2) and used to calculate lumbar SMI (cm2/m2). This study was performed in accordance with the Japanese Ethical Guidelines for Medical and Health Research Involving Humans and approved by the Ethical Committee of our facility. Results The median pre-transplant lumber SMI of the male patients was significantly higher than that of the female patients (42.7 (24.9-60.2) mm2/m2 vs. 31.9 (20.7-44.6) mm2/m2, p<0.01). We defined the cutoff value of lumber SMI as 42.7cm2/m2 for male and 31.9cm2/m2 for female patients. In the Kaplan-Meier estimate analysis, low lumber SMI was a significant poor prognostic factor for overall survival (p=0.016). In multivariate analysis using Cox regression model, adjusting for age, refined disease risk index, conditioning and HCT-CI, low lumber SMI was extracted as a significant poor prognostic factor for overall survival (hazard ratio 1.56, 95% confidence interval (CI) 1.03-2.36, p=0.036). By logistic regression analysis, adjusted odds ratio of 1-year non-relapse mortality for low lumber SMI was 2.47 (95% CI 1.13-5.41, p=0.024). Conclusion Low pre-transplant lumber SMI is a significant poor prognostic factor in allo-HCT, independent of other risk factors including HCT-CI and refined disease risk index in patients with hematological disease. It is affected by the high rate of non-relapse mortality in the early phase following allo-HCT in patients with low lumber SMI. Disclosures No relevant conflicts of interest to declare.


Nutrition ◽  
2018 ◽  
Vol 50 ◽  
pp. e9-e10
Author(s):  
D. Basile ◽  
A. Bacco ◽  
A. Parnofiello ◽  
M.G. Vitale ◽  
F. Cortiula ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document